Groundbreaking Study Suggests Ozempic & Wegovy Could Slow Biological Aging
A groundbreaking new clinical study published in Nature Communications has unveiled that semaglutide — the active ingredient in the highly successful weight-loss drugs Ozempic and Wegovy — could potentially do more than just reduce waistlines. Researchers from the esteemed UC San Diego’s School of Medicine discovered that this drug could slow down markers of biological aging in adults. This marks the first-ever randomized, placebo-controlled clinical evidence suggesting that a GLP-1 medication could influence the rate at which the human body ages.
The trial involved 108 adults suffering from HIV-associated lipohypertrophy — a condition closely associated with accelerated biological aging. These participants were administered either weekly semaglutide injections or a placebo over a span of 32 weeks. The scientists didn’t measure aging based on the birth year, but instead used epigenetic clocks. These clocks analyze DNA methylation patterns to estimate an individual’s biological age. Participants who received semaglutide demonstrated a 9% slowdown in the pace of biological aging. This was measured by the DunedinPACE epigenetic clock, with improvements observed across markers related to the heart, brain, kidneys, liver, and metabolic system.
“Semaglutide has far-reaching benefits beyond what we initially imagined,” stated Professor Harlan Krumholz of Yale School of Medicine. While the researchers advise that further study is required before making broad anti-aging claims, these findings open up an exciting new frontier in longevity medicine. This could potentially reshape how millions perceive the most discussed drug globally.
Source: ScienceDaily – Ozempic and Wegovy May Slow Biological Aging (July 14, 2026)